Kiadis Pharma rais­es €18.0 mil­lion in a pri­vate place­ment of 2.25 mil­lion new shares

Amsterdam-Duivendrecht, The Netherlands, October 10, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive prod­ucts to make bone mar­row trans­plan­ta­tions safer and more effec­tive for patients suf­fer­ing from blood can­cers and inher­it­ed blood dis­or­ders, today announces that it has raised gross pro­ceeds of €18 mil­lion through an undoc­u­ment­ed pri­vate place­ment of 2.25 mil­lion new shares to insti­tu­tion­al investors via an accel­er­at­ed book­build­ing process as announced on October 9, 2017 (the “Placing”). The Placing was com­plet­ed at a sub­scrip­tion price of €8.00 per share and rep­re­sent­ed 15.0% of the issued share cap­i­tal of the Company pri­or to the trans­ac­tion.

The new ordi­nary shares will rank pari pas­su in all respects with the cur­rent­ly out­stand­ing shares of the com­pa­ny and are expect­ed to be list­ed and trad­ed on Euronext Amsterdam and Brussels on October 12, 2017. Following the Placing, the issued share cap­i­tal of the Company will be 17,287,397.
The pro­ceeds from the Placing, com­bined with €2.3 mil­lion received by Kiadis Pharma from the exer­cise of war­rants placed pur­suant to the Company’s pri­vate place­ment of June 13, 2017, will allow the com­pa­ny to draw down an addi­tion­al €5 mil­lion of debt financ­ing from Kreos Capital as announced on August 17, 2017.

Kiadis Pharma intends to use the net pro­ceeds of the Placing to:
– advance the Phase III inter­na­tion­al, ran­dom­ized, con­trolled, mul­ti­cen­tre clin­i­cal tri­al for ATIR101TM in the United States, Canada and Europe;
– secure addi­tion­al man­u­fac­tur­ing capac­i­ty at ven­dors and lease its own com­mer­cial
man­u­fac­tur­ing facil­i­ty;
– pre­pare Kiadis Pharma for launch of ATIR101TM in the EU in 2019 by invest­ing in med­ical affairs, mar­ket access prepa­ra­tion and re-imburse­ment dis­cus­sions;
– pur­sue ATIR201TM and a new study com­bin­ing ATIR101TM with the Baltimore pro­to­col and/or
anoth­er T-cell deplet­ed hematopoi­et­ic stem cell trans­plan­ta­tion;
– expand the orga­ni­za­tion to accom­mo­date the increased num­ber of activ­i­ties;
– apply funds for debt repay­ment, cap­i­tal expen­di­ture, gen­er­al and admin­is­tra­tive expens­es, gen­er­al cor­po­rate pur­pos­es in line with Kiadis Pharma’s strat­e­gy and oth­er work­ing cap­i­tal needs.
Arthur Lahr, CEO of Kiadis Pharma, com­ment­ed: “With this €18 mil­lion pri­vate place­ment, the €2.3 mil­lion pro­ceeds from war­rants, and the €5 mil­lion tranche from Kreos Capital once drawn down, Kiadis Pharma will add a total of €25 mil­lion to its bal­ance sheet. This will fund the Company into 2019 and thus beyond the poten­tial H2 2018 (con­di­tion­al) approval of ATIR101TM in Europe.
The offer­ing was over­sub­scribed and we have now reached the max­i­mum num­ber of shares that can be added to our list­ing with­out the pub­li­ca­tion of a prospec­tus. We are pleased to see exist­ing share­hold­ers increase their hold­ings and wel­come a num­ber of new investors.
Kiadis Pharma is well on track to bring ATIR to patients, to help address the high rates of relapse and graft ver­sus host dis­ease with cur­rent trans­plan­ta­tion approach­es.

Jefferies International Limited act­ed as Sole Bookrunner and Canaccord Genuity Limited and Oppenheimer & Co. Inc. act­ed as Lead Managers in con­nec­tion with the Placing. Chardan and Saola Healthcare Partners act­ed as finan­cial advi­sors to the Company.

Leave a Reply

Your email address will not be published. Required fields are marked *